Open Access Full Text Article

CORRIGENDUM

Corrigendum

Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Banerjee S, Staudinger H. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. *Int J Chron Obstruct Pulmon Dis*. 2012;7:43–55.

In Table 4, the value at column 5, row 15 should have been 4 instead of 2. The corrected table is below.

Table 4 Summary of treatment-emergent adverse events

	Number of subjects (%)				
	MF/F 200/10 µg bid (n = 207)	**MF/F 400/10 µg bid (n = 217)**	**MF 400 µg bid (n = 210)**	**F 10 µg bid (n = 209)**	**Placebo bid (n = 212)**
Treatment period (weeks 1–26)					
Any AE	62 (30.0)	57 (26.3)	62 (29.5)	70 (33.5)	67 (31.6)
Severe or life-threatening AEs	6 (2.9)	9 (4.1)	15 (7.1)	16 (7.7)	12 (5.7)
Life-threatening AEs	0	4 (1.8)	4 (1.9)	4 (1.9)	3 (1.4)
Serious AEs	8 (3.9)	16 (7.4)	15 (7.1)	17 (8.1)	12 (5.7)
Discontinuations due to AEs	2 (1.0)	10 (4.6)	9 (4.3)	6 (2.9)	8 (3.8)
Deaths	1 (0.4)	1 (0.4)	3 (1.4)	3 (1.4)	1 (0.4)
Pneumonia	1 (0.5)	2 (0.9)	0	2 (1.0)	1 (0.5)
Treatment-related AEs	9 (4.3)	13 (6.0)	12 (5.7)	15 (7.2)	10 (4.7)
Treatment period + safety extension (weeks 1–52)					
Any AE	78 (37.7)	78 (35.9)	86 (41.07)	88 (42.1)	
Severe or life-threatening AEs	7 (3.4)	21 (9.7)	19 (9.0)	24 (11.5)	
Life-threatening AEs	1 (0.5)	6 (2.8)	4 (1.9)	6 (2.9)	
Serious AEs	13 (6.3)	29 (13.4)	22 (10.5)	29 (13.9)	
Discontinuations due to AEs	4 (1.9)	14 (6.5)	13 (6.2)	11 (5.3)	
Deaths	1 (0.4)	3 (1.3)	3 (1.4)	8 (3.8)	
Pneumonia	1 (0.5)	4 (1.8)	2 (1.0)	4 (1.9)	
Treatment-related AEs	12 (5.8)	18 (8.3)	15 (7.1)	17 (8.1)	

Abbreviations: AE, adverse event; bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.